Peer-Reviewed Publication
Health Aff (Millwood)2025;44(3):246-255.March 1, 2025Journal Article
Demographic Variation In US Outpatient Hydroxychloroquine And Ivermectin Use During The COVID-19 Pandemic.
Michelle S Rockwell1, Sitaram Vangala2, Michael Hadfield3, Jonathan Cantor4, Dale Skinner5, Melody Craff6, A Mark Fendrick7, Cheryl L Damberg8, Katherine Kahn9, John N Mafi10
1Michelle S. Rockwell (msrock@vt.edu), Virginia Polytechnic Institute and State University, Roanoke, Virginia.
2Sitaram Vangala, University of California Los Angeles, Los Angeles, California.
3Michael Hadfield, Milliman Medinsight, Seattle, Washington.
4Jonathan Cantor, RAND Corporation, Santa Monica, California.
5Dale Skinner, Milliman Medinsight.
6Melody Craff, Milliman Medinsight.
7A. Mark Fendrick, University of Michigan, Ann Arbor, Michigan.
8Cheryl L. Damberg, RAND Corporation.
9Katherine Kahn, University of California Los Angeles and RAND Corporation.
10John N. Mafi, University of California Los Angeles and RAND Corporation.
Abstract
As COVID-19 surged across the US starting in 2020, so too did the use of repurposed medications such as hydroxychloroquine and ivermectin to treat COVID-19 infections. Use of these medications throughout the public health emergency and across demographic subgroups is not well understood. Using insurance claims from the MedInsight Emerging Experience Research Database for 8.1 million patients from…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans